Opdualag®

LAG-3 inhibitor (in combination with nivolumab, a PD-1 inhibitor)

160 mg IV every 4 weeks given with nivolumab

• Canadian funding supports fixed dosing when given in combination with nivolumab.

160 mg IV every 4 weeks

160 mg

Until PD or unacceptable toxicity.

• Nivolumab (Metastatic melanoma) - 160 mg IV every 4 weeks

All doses administered IV over 30 minutes.

80 mg (20 mL vial combined with 240 mg of nivolumab)

Dose relationship with efficacy and toxicity has not been well established.

• Limited evidence suggests higher doses of relatlimab may be associated with increased toxicity based on two cases of rapid-onset myocarditis with nivolumab 480 mg + relatlimab 960 mg every 4 weeks.

26 days (130 days)

• Exhibits non-linear and time-varying pharmacokinetics when administered at a dose of 160 mg IV every 4 weeks.

• Relatlimab can impact functionality of other immune cells, such as natural killer cells, promoting their activity and enhancing the ability to recognize and attack melanoma cells.